{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:14:13Z","timestamp":1762640053759,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T00:00:00Z","timestamp":1607472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00066-020-01721-w","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:21:26Z","timestamp":1607534486000},"page":"711-721","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The risk of late effects following pediatric and adult radiotherapy regimens in Hodgkin lymphoma"],"prefix":"10.1007","volume":"197","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-888X","authenticated-orcid":false,"given":"Anni Young","family":"Lundgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa Lyngsie","family":"Hjalgrim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Ann","family":"Rechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lundemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. Patrik","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Joergensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Specht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja Vestmoe","family":"Maraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,9]]},"reference":[{"key":"1721_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJCK (eds) SEER Cancer Statistics Review, 1975\u20132016, National Cancer Institute. Bethesda, MD. https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. n.\u202fd. Accessed 19 Dec 2019"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","volume":"21","author":"BMP Aleman","year":"2003","unstructured":"Aleman\u00a0BMP, van den Belt-Dusebout\u00a0AW, Klokman\u00a0WJ, van\u2019t Veer\u00a0MB, Bartelink\u00a0H, van Leeuwen\u00a0FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease. J\u00a0Clin Oncol 21:3431\u20133439. https:\/\/doi.org\/10.1200\/JCO.2003.07.131","journal-title":"J Clin Oncol"},{"key":"1721_CR3","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld\u00a0M, Aleman\u00a0BMP, van Eggermond\u00a0AM, Janus\u00a0CPM, Krol\u00a0ADG, van der Maazen\u00a0RWM et\u00a0al (2015) Second cancer risk up to 40 years after treatment for Hodgkin\u2019s Lymphoma. N\u00a0Engl J Med 373:2499\u20132511. https:\/\/doi.org\/10.1056\/NEJMoa1505949","journal-title":"N Engl J Med"},{"key":"1721_CR4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796.An","volume":"117","author":"SM Castellino","year":"2011","unstructured":"Castellino\u00a0SM, Geiger\u00a0AM, Mertens\u00a0AC, Leisenring\u00a0WM, Tooze\u00a0JA, Goodman\u00a0P et al (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the Childhood Cancer Survivor Study. Blood 117:1806\u20131816. https:\/\/doi.org\/10.1182\/blood-2010-04-278796.An","journal-title":"Blood"},{"key":"1721_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","volume":"17","author":"N Bhakta","year":"2016","unstructured":"Bhakta\u00a0N, Liu\u00a0Q, Yeo\u00a0F, Baassiri\u00a0M, Ehrhardt\u00a0MJ, Srivastava\u00a0DK et\u00a0al (2016) Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol 17:1325\u20131334. https:\/\/doi.org\/10.1016\/S1470-2045(16)30215-7","journal-title":"Lancet Oncol"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","volume":"31","author":"W D\u00f6rffel","year":"2013","unstructured":"D\u00f6rffel\u00a0W, R\u00fchl\u00a0U, L\u00fcders\u00a0H, Claviez\u00a0A, Albrecht\u00a0M, B\u00f6kkerink\u00a0J et al (2013) Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J\u00a0Clin Oncol 31:1562\u20131568. https:\/\/doi.org\/10.1200\/JCO.2012.45.3266","journal-title":"J Clin Oncol"},{"key":"1721_CR7","unstructured":"K\u00f6rholz D, L\u2011PJ WWH Euro-Net-PHL-C1 n.\u202fd. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00433459. Accessed 2 Jan 2018"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.prro.2014.05.003","volume":"5","author":"DC Hodgson","year":"2015","unstructured":"International Lymphoma Radiation Oncology Group, Hodgson\u00a0DC, Dieckmann\u00a0K, Terezakis\u00a0S, Constine\u00a0L (2015) Implementation of contemporary radiation therapy planning concepts for pediatric Hodgkin lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. Pract Radiat Oncol 5:85\u201392. https:\/\/doi.org\/10.1016\/j.prro.2014.05.003","journal-title":"Pract Radiat Oncol"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9\u00a0MPE, Girinsky\u00a0T, Federico\u00a0M, Reman\u00a0O, Fortpied\u00a0C, Gotti\u00a0M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J\u00a0Clin Oncol 35:1786\u20131794. https:\/\/doi.org\/10.1200\/JCO.2016.68.6394","journal-title":"J Clin Oncol"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert\u00a0A, Pl\u00fctschow\u00a0A, Eich\u00a0HT, Lohri\u00a0A, D\u00f6rken\u00a0B, Borchmann\u00a0P et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin\u2019s Lymphoma. N\u00a0Engl J Med 363:640\u2013652. https:\/\/doi.org\/10.1056\/NEJMoa1000067","journal-title":"N Engl J Med"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","volume":"28","author":"HT Eich","year":"2010","unstructured":"Eich\u00a0HT, Diehl\u00a0V, G\u00f6rgen\u00a0H, Pabst\u00a0T, Markova\u00a0J, Debus\u00a0J et al (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the german hodgkin study group HD11 trial. J\u00a0Clin Oncol 28:4199\u20134206. https:\/\/doi.org\/10.1200\/JCO.2010.29.8018","journal-title":"J Clin Oncol"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","volume":"89","author":"L Specht","year":"2014","unstructured":"Specht\u00a0L, Yahalom\u00a0J, Illidge\u00a0T, Berthelsen\u00a0AK, Constine\u00a0LS, Eich\u00a0HT et\u00a0al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854\u2013862. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1721_CR13","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","volume":"379","author":"A Engert","year":"2012","unstructured":"Engert\u00a0A, Haverkamp\u00a0H, Kobe\u00a0C, Markova\u00a0J, Renner\u00a0C, Ho\u00a0A et al (2012) Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a\u00a0randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791\u20131799. https:\/\/doi.org\/10.1016\/S0140-6736(11)61940-5","journal-title":"Lancet"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/cncr.30979","volume":"124","author":"TO Henderson","year":"2018","unstructured":"Henderson\u00a0TO, Parsons\u00a0SK, Wroblewski\u00a0KE, Chen\u00a0L, Hong\u00a0F, Smith\u00a0SM et\u00a0al (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136\u2013144. https:\/\/doi.org\/10.1002\/cncr.30979","journal-title":"Cancer"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1182\/blood-2018-01-778548","volume":"132","author":"JE Flerlage","year":"2018","unstructured":"Flerlage\u00a0JE, Metzger\u00a0ML, Bhakta\u00a0N (2018) The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice? Blood 132:376\u2013384. https:\/\/doi.org\/10.1182\/blood-2018-01-778548","journal-title":"Blood"},{"key":"1721_CR16","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","volume":"112","author":"C Kobe","year":"2008","unstructured":"Kobe\u00a0C, Dietlein\u00a0M, Franklin\u00a0J, Markova\u00a0J, Lohri\u00a0A, Amthauer\u00a0H et al (2008) Positron emission tomography has a\u00a0high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989\u20133994. https:\/\/doi.org\/10.1182\/blood-2008-06-155820","journal-title":"Blood"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","volume":"79","author":"M Feng","year":"2011","unstructured":"Feng\u00a0M, Moran\u00a0JM, Koelling\u00a0T, Chughtai\u00a0A, Chan\u00a0JL, Freedman\u00a0L et\u00a0al (2011) Development and validation of a\u00a0heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 79:10\u201318. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.058","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis\u00a0LB, Gospodarowicz\u00a0M, Curtis\u00a0RE, Clarke\u00a0EA, Andersson\u00a0M, Glimelius\u00a0B et\u00a0al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease. J\u00a0Natl Cancer Inst 94:182\u2013192","journal-title":"J Natl Cancer Inst"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","volume":"290","author":"LB Travis","year":"2003","unstructured":"Travis\u00a0LB, Hill\u00a0DA, Dores\u00a0GM, Gospodarowicz\u00a0M, van Leeuwen\u00a0FE, Holowaty\u00a0E et\u00a0al (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290:465. https:\/\/doi.org\/10.1001\/jama.290.4.465","journal-title":"JAMA"},{"key":"1721_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv008","author":"DJ Cutter","year":"2015","unstructured":"Cutter\u00a0DJ, Schaapveld\u00a0M, Darby\u00a0SC, Hauptmann\u00a0M, Van Nimwegen\u00a0FA, Krol\u00a0ADG et\u00a0al (2015) Risk for valvular heart disease after treatment for Hodgkin Lymphoma. JNCI J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv008","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1721_CR21","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney\u00a0DA, Yeazel\u00a0MW, Kawashima\u00a0T, Mertens\u00a0AC, Mitby\u00a0P, Stovall\u00a0M et\u00a0al (2009) Cardiac outcomes in a\u00a0cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606. https:\/\/doi.org\/10.1136\/bmj.b4606","journal-title":"BMJ"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1667\/RR2240.1","volume":"174","author":"P Bhatti","year":"2010","unstructured":"Bhatti\u00a0P, Veiga\u00a0LHS, Ronckers\u00a0CM, Sigurdson\u00a0AJ, Stovall\u00a0M, Smith\u00a0SA et\u00a0al (2010) Risk of second primary thyroid cancer after radiotherapy for a\u00a0childhood cancer in a\u00a0large cohort study: an update from the childhood cancer survivor study. Radiat Res 174:741\u2013752. https:\/\/doi.org\/10.1667\/RR2240.1","journal-title":"Radiat Res"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.01.073","volume":"75","author":"AW van den Belt-Dusebout","year":"2009","unstructured":"van den Belt-Dusebout\u00a0AW, Aleman\u00a0BMP, Besseling\u00a0G, de Bruin\u00a0ML, Hauptmann\u00a0M, van \u2019t Veer\u00a0MB et al (2009) Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a\u00a0second malignancy. Int J Radiat Oncol Biol Phys 75:1420\u20131429. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.01.073","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1721_CR24","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KAEB (eds) SEER Cancer Statistics Review, 1975\u20132008, National Cancer Institute. Bethesda, MD. Based Novemb 2010 SEER Data Submission, Posted to SEER Web Site, 2011 n.\u202fd. http:\/\/seer.cancer.gov\/csr\/1975_2008\/. Accessed June 14 2011"},{"key":"1721_CR25","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics Health data interactive n.\u202fd. www.cdc.gov\/nchs\/hdi.htm. Accessed Jan 11 2011"},{"key":"1721_CR26","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.1002\/cncr.27536","volume":"118","author":"NP Brodin","year":"2012","unstructured":"Brodin\u00a0NP, Vogelius\u00a0IR, Maraldo\u00a0MV, Munck af Rosensch\u00f6ld\u00a0P, Aznar\u00a0MC, Kiil-Berthelsen\u00a0A et al (2012) Life years lost-comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a\u00a0common scale. Cancer 118:5432\u20135440. https:\/\/doi.org\/10.1002\/cncr.27536","journal-title":"Cancer"},{"key":"1721_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.radonc.2017.07.033","volume":"125","author":"LA Rechner","year":"2017","unstructured":"Rechner\u00a0LA, Maraldo\u00a0MV, Vogelius\u00a0IR, Zhu\u00a0XR, Dabaja\u00a0BS, Brodin\u00a0NP et\u00a0al (2017) Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: the impact of proton therapy and\/or deep inspiration breath hold. Radiother Oncol 125:41\u201347. https:\/\/doi.org\/10.1016\/j.radonc.2017.07.033","journal-title":"Radiother Oncol"},{"key":"1721_CR28","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/jnci\/djn310","volume":"100","author":"AC Mertens","year":"2008","unstructured":"Mertens\u00a0AC, Liu\u00a0Q, Neglia\u00a0JP, Wasilewski\u00a0K, Leisenring\u00a0W, Armstrong\u00a0GT et al (2008) Cause-specific late mortality among 5\u2011year survivors of childhood cancer: the childhood cancer survivor study. JNCI J Natl Cancer Inst 100:1368\u20131379. https:\/\/doi.org\/10.1093\/jnci\/djn310","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1721_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","volume":"368","author":"VT Nkomo","year":"2006","unstructured":"Nkomo\u00a0VT, Gardin\u00a0JM, Skelton\u00a0TN, Gottdiener\u00a0JS, Scott\u00a0CG, Enriquez-Sarano\u00a0M (2006) Burden of valvular heart diseases: a\u00a0population-based study. Lancet 368:1005\u20131011. https:\/\/doi.org\/10.1016\/S0140-6736(06)69208-8","journal-title":"Lancet"},{"issue":"4","key":"1721_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/pbc.24861","volume":"61","author":"MV Maraldo","year":"2014","unstructured":"Maraldo\u00a0MV, J\u00f8rgensen\u00a0M, Brodin\u00a0NP, Aznar\u00a0MC, Vogelius\u00a0IR, Petersen\u00a0PM, Berthelsen\u00a0AK, Christensen\u00a0CB, Hjalgrim\u00a0LL, Specht\u00a0L (2014) The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 61 (4):717\u2013722","journal-title":"Pediatr Blood Cancer"},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.ijrobp.2014.06.069","volume":"90","author":"MV Maraldo","year":"2014","unstructured":"Maraldo\u00a0MV, Specht\u00a0L (2014) A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn? Int J Radiat Oncol Biol Phys 90:1126\u20131135. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.06.069","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1721_CR32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(18)30903-3","volume":"20","author":"CJ Bright","year":"2019","unstructured":"Bright\u00a0CJ, Reulen\u00a0RC, Winter\u00a0DL, Stark\u00a0DP, McCabe\u00a0MG, Edgar\u00a0AB et al (2019) Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a\u00a0population-based, cohort study. Lancet Oncol 20:531\u2013545. https:\/\/doi.org\/10.1016\/S1470-2045(18)30903-3","journal-title":"Lancet Oncol"},{"key":"1721_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/dju110","volume":"106","author":"K Rugbjerg","year":"2014","unstructured":"Rugbjerg\u00a0K, Mellemkj\u00e6r\u00a0L, Boice\u00a0JD, Kober\u00a0L, Ewertz\u00a0M, Olsen\u00a0JH (2014) Cardiovascular disease in survivors of adolescent and young adult cancer: a danish cohort study, 1943\u20132009. J\u00a0Natl Cancer Inst 106:1\u201310. https:\/\/doi.org\/10.1093\/jnci\/dju110","journal-title":"J Natl Cancer Inst"},{"key":"1721_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7326\/M15-0424","volume":"164","author":"DA Mulrooney","year":"2016","unstructured":"Mulrooney\u00a0DA, Armstrong\u00a0GT, Huang\u00a0S, Ness\u00a0KK, Ehrhardt\u00a0MJ, Joshi\u00a0VM et\u00a0al (2016) Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy. Ann Intern Med 164:93\u2013101. https:\/\/doi.org\/10.7326\/M15-0424","journal-title":"Ann Intern Med"},{"key":"1721_CR35","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen\u00a0FA, Ntentas\u00a0G, Darby\u00a0SC, Schaapveld\u00a0M, Hauptmann\u00a0M, Lugtenburg\u00a0PJ et\u00a0al (2017) Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood 129:2257\u20132265. https:\/\/doi.org\/10.1182\/blood-2016-09-740332","journal-title":"Blood"},{"key":"1721_CR36","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.ijrobp.2017.03.026","volume":"98","author":"E Hahn","year":"2017","unstructured":"Hahn\u00a0E, Jiang\u00a0H, Ng\u00a0A, Bashir\u00a0S, Ahmed\u00a0S, Tsang\u00a0R et al (2017) Late cardiac toxicity after mediastinal radiation therapy for Hodgkin Lymphoma: contributions of coronary artery and whole heart dose-volume variables to risk prediction. Int J Radiat Oncol 98:1116\u20131123. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.03.026","journal-title":"Int J Radiat Oncol"},{"key":"1721_CR37","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","volume":"2","author":"MV Maraldo","year":"2015","unstructured":"Maraldo\u00a0MV, Giusti\u00a0F, Vogelius\u00a0IR, Lundemann\u00a0M, van der Kaaij\u00a0MAE, Ramadan\u00a0S et al (2015) Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2:e492\u2013e502. https:\/\/doi.org\/10.1016\/S2352-3026(15)00153-2","journal-title":"Lancet Haematol"},{"key":"1721_CR38","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa1209825","volume":"368","author":"SC Darby","year":"2013","unstructured":"Darby\u00a0SC, Ewertz\u00a0M, McGale\u00a0P, Bennet\u00a0AM, Blom-Goldman\u00a0U, Br\u00f8nnum\u00a0D et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N\u00a0Engl J Med 368:987\u2013998. https:\/\/doi.org\/10.1056\/NEJMoa1209825","journal-title":"N Engl J Med"},{"key":"1721_CR39","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","volume":"30","author":"SL Wolden","year":"2012","unstructured":"Wolden\u00a0SL, Chen\u00a0L, Kelly\u00a0KM, Herzog\u00a0P, Gilchrist\u00a0GS, Thomson\u00a0J et al (2012) Long-term results of CCG 5942: a\u00a0randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group. J\u00a0Clin Oncol 30:3174\u20133180. https:\/\/doi.org\/10.1200\/JCO.2011.41.1819","journal-title":"J Clin Oncol"},{"key":"1721_CR40","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","volume":"32","author":"DL Friedman","year":"2014","unstructured":"Friedman\u00a0DL, Chen\u00a0L, Wolden\u00a0S, Buxton\u00a0A, McCarten\u00a0K, FitzGerald\u00a0TJ et al (2014) Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a\u00a0report from the Children\u2019s Oncology Group Study AHOD0031. J\u00a0Clin Oncol 32:3651\u20133658. https:\/\/doi.org\/10.1200\/JCO.2013.52.5410","journal-title":"J Clin Oncol"},{"key":"1721_CR41","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford\u00a0J, Illidge\u00a0T, Counsell\u00a0N, Hancock\u00a0B, Pettengell\u00a0R, Johnson\u00a0P et al (2015) Results of a\u00a0trial of PET-directed therapy for early-stage Hodgkin\u2019s Lymphoma. N\u00a0Engl J Med 372:1598\u20131607. https:\/\/doi.org\/10.1056\/NEJMoa1408648","journal-title":"N Engl J Med"},{"key":"1721_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2015.62.3314","volume":"34","author":"TO Henderson","year":"2016","unstructured":"Henderson\u00a0TO, Moskowitz\u00a0CS, Chou\u00a0JF, Bradbury\u00a0AR, Neglia\u00a0JP, Dang\u00a0CT et\u00a0al (2016) Breast cancer risk in childhood cancer survivors without a\u00a0history of chest radiotherapy: a report from the childhood cancer survivor study. J\u00a0Clin Oncol 34:910\u2013918. https:\/\/doi.org\/10.1200\/JCO.2015.62.3314","journal-title":"J Clin Oncol"},{"key":"1721_CR43","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1200\/JCO.2016.71.6902","volume":"35","author":"JC Teepen","year":"2017","unstructured":"Teepen\u00a0JC, van Leeuwen\u00a0FE, Tissing\u00a0WJ, van Dulmen-den Broeder\u00a0E, van den Heuvel-Eibrink\u00a0MM, van der Pal\u00a0HJ et al (2017) Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J\u00a0Clin Oncol 35:2288\u20132298. https:\/\/doi.org\/10.1200\/JCO.2016.71.6902","journal-title":"J Clin Oncol"},{"key":"1721_CR44","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1001\/jamapediatrics.2019.3807","volume":"173","author":"LH Veiga","year":"2019","unstructured":"Veiga\u00a0LH, Curtis\u00a0RE, Morton\u00a0LM, Withrow\u00a0DR, Howell\u00a0RM, Smith\u00a0SA et\u00a0al (2019) Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use. JAMA Pediatr 173:1171. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.3807","journal-title":"JAMA Pediatr"},{"key":"1721_CR45","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","volume":"10","author":"BS Hoppe","year":"2020","unstructured":"Hoppe\u00a0BS, Bates\u00a0JE, Mendenhall\u00a0NP, Morris\u00a0CG, Louis\u00a0D, Ho\u00a0MW et\u00a0al (2020) The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol 10:e147\u2013e154. https:\/\/doi.org\/10.1016\/j.prro.2019.09.015","journal-title":"Pract Radiat Oncol"},{"key":"1721_CR46","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.semradonc.2007.02.009","volume":"17","author":"DC Hodgson","year":"2007","unstructured":"Hodgson\u00a0DC, Hudson\u00a0MM, Constine\u00a0LS (2007) Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol 17:230\u2013242. https:\/\/doi.org\/10.1016\/j.semradonc.2007.02.009","journal-title":"Semin Radiat Oncol"},{"key":"1721_CR47","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","volume":"82","author":"A Paumier","year":"2012","unstructured":"Paumier\u00a0A, Ghalibafian\u00a0M, Gilmore\u00a0J, Beaudre\u00a0A, Blanchard\u00a0P, el Nemr\u00a0M et al (2012) Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s Lymphoma. Int J Radiat Oncol 82:1522\u20131527. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.015","journal-title":"Int J Radiat Oncol"},{"key":"1721_CR48","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2014.932435","author":"PM Petersen","year":"2014","unstructured":"Petersen\u00a0PM, Aznar\u00a0MC, Berthelsen\u00a0AK, Loft\u00a0A, Schut\u00a0DA, Maraldo\u00a0M et al (2014) Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: Benefit of deep inspiration breath-hold. Acta Oncol. https:\/\/doi.org\/10.3109\/0284186X.2014.932435","journal-title":"Acta Oncol"},{"key":"1721_CR49","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.ijrobp.2014.04.029","volume":"89","author":"BS Hoppe","year":"2014","unstructured":"Hoppe\u00a0BS, Flampouri\u00a0S, Zaiden\u00a0R, Slayton\u00a0W, Sandler\u00a0E, Ozdemir\u00a0S et al (2014) Involved-node proton therapy in combined modality therapy for Hodgkin Lymphoma: results of a\u00a0phase 2 study. Int J Radiat Oncol 89:1053\u20131059. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.04.029","journal-title":"Int J Radiat Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01721-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-020-01721-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-020-01721-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T13:04:44Z","timestamp":1626786284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-020-01721-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s00066-020-01721-w","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"L.\u00a0Specht is on advisory boards and received honoraria from Takeda and Kyowa Kirin. She has research grants from Varian and ViewRay. A.Y.\u00a0Lundgaard, L.L.\u00a0Hjalgrim, L.A.\u00a0Rechner, M.\u00a0Lundemann, N.P.\u00a0Brodin, M.\u00a0Joergensen, and M.V.\u00a0Maraldo declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Danish Patient Safety Authority (3-3013-1953\/1) and the Danish Data Protection Agency (RH-2017-28).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}